Gujarat Inject (Kerala) Board of Directors
Get the latest insights into the leadership at Gujarat Inject (Kerala). Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Murli Nair | Chairman & Wholetime Director |
| Ms. Reena Mahatma | Non Executive Director |
| Mr. Rushiraj Zaverbhai Patel | Non Exe. & Ind. Director |
| Mr. Nileshbhai Vinubhai Rangholiya | Non Exe. & Ind. Director |
Gujarat Inject (Kerala) Share price
GUJINJEC
31.5
0.69 (2.24%)Last updated on 16 Dec, 2025 | 14:58 IST
BUYSELL
Today's High
32.00
Today's Low
30.10
52 Week Low
17.02
52 Week High
32.00
The current prices are delayed, login to your account for live prices
Login Gujarat Inject (Kerala) FAQs
The board at Gujarat Inject (Kerala) consists of experienced professionals, including Mr. Murli Nair , Ms. Reena Mahatma , and others, overseeing the company’s strategic and corporate governance.
Directors at Gujarat Inject (Kerala) are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Murli Nair is the current chairman at Gujarat Inject (Kerala).
Executive directors at Gujarat Inject (Kerala) are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Gujarat Inject (Kerala) adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Gujarat Inject (Kerala), board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
